Nawal Kassem

Hematology | Oncology

535 Barnhill Dr
Indianapolis, IN 46202

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology.

Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: December 17, 2024

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: October 19, 2023

Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE.

Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE.

Journal: British journal of cancer

Published: October 08, 2023

Clinically significant germline pathogenic variants are missed by tumor genomic sequencing.

Clinically significant germline pathogenic variants are missed by tumor genomic sequencing.

Journal: NPJ genomic medicine

Published: May 24, 2023

Racial disparities in cascade testing for cancer predisposition genes.

Racial disparities in cascade testing for cancer predisposition genes.

Journal: Preventive medicine

Published: February 03, 2023

Reply to K. Nozawa et al.

Reply to K. Nozawa et al.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 31, 2022

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 15, 2021

Identification of germline cancer predisposition variants during clinical ctDNA testing.

Identification of germline cancer predisposition variants during clinical ctDNA testing.

Journal: Scientific reports

Published: February 18, 2021

Implications of Incidental Germline Findings Identified In the Context of Clinical Whole Exome Sequencing for Guiding Cancer Therapy.

Implications of Incidental Germline Findings Identified In the Context of Clinical Whole Exome Sequencing for Guiding Cancer Therapy.

Journal: JCO precision oncology

Published: November 01, 2020

Precision Prevention: The Current State and Future of Genomically Guided Cancer Prevention.

Precision Prevention: The Current State and Future of Genomically Guided Cancer Prevention.

Journal: JCO precision oncology

Published: November 01, 2020

Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.

Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 23, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026